-
Multiple sclerosis has a long way to explore, and disease modification therapy will still seek ECTRIMS 2022
Time of Update: 2023-01-06
Figure 1: BTK inhibitors significantly reduced disease scores and serum NfH levels in EAE mice▌ Not afraid of the test, the efficacy and safety of treatment for up to 2 years are still goodA phase 2b study published in the top journal The Lancet Neurology in 2021 showed that 12 weeks of tolebrutinib treatment resulted in a dose-dependent reduction in the number of new gadolinium-enhancing lesions in MS patients with a favorable safety profile [7].
-
Multiple sclerosis has a long way to explore, and disease modification therapy will still seek ECTRIMS 2022
Time of Update: 2023-01-06
Figure 1: BTK inhibitors significantly reduced disease scores and serum NfH levels in EAE mice▌ Not afraid of the test, the efficacy and safety of treatment for up to 2 years are still goodA phase 2b study published in the top journal The Lancet Neurology in 2021 showed that 12 weeks of tolebrutinib treatment resulted in a dose-dependent reduction in the number of new gadolinium-enhancing lesions in MS patients with a favorable safety profile [7].
-
J Clin Oncol: Long-term prognosis of daratumumab in combination with bortezomib and dexamethasone in multiple myeloma
Time of Update: 2023-01-04
The trial was a multicenter, randomized, open-label, Phase 3 study enrolling patients with relapsed or refractory multiple myeloma who had previously received ≥ 1st line therapy and were randomized to Vd (up to 8 courses) or Vd + daratumumab (D-Vd) (treatment until disease progression).
-
Adults living in areas with high levels of air pollution are more likely to suffer from multiple long-term health problems
Time of Update: 2023-01-01
A new UK study of 364,000 people shows that exposure to traffic-related air pollution increases the likelihood of multiple long-term physical and mental health problems.
-
New drug for multiple sclerosis (MS)! CNS osmotic covalent BTK inhibitor evobrutinib: 3.5 years of treatment, showing long-lasting clinical benefits!
Time of Update: 2022-11-04
The open-label extension (OLE) section of the Phase II clinical trial evaluated the long-term therapeutic effect of evobrutinib on ARR, EDSS scores and several magnetic resonance imaging (MRI) results in RMS patients: throughout the course of OLE, the ARR remained low at 0.
-
Pembrolizumab helps patients with multiple types of advanced tumors achieve long-term survival
Time of Update: 2022-10-20
At the 2022 European Medical Oncology (ESMO) Congress that concluded on September 13, the five-year survival follow-up data of multiple immunotherapy combined with chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) were released, including Merck's PD-1 inhibitor pembrolizumab (commonly known as "K drug") combined with chemotherapy.
-
A new breakthrough in CAR-T cell therapy: successfully treating multiple patients with lupus erythematosus and achieving long-term drug-free remission
Time of Update: 2022-10-03
Written by Editor Wang DuoyuTypesettingWater into writingSystemic lupus erythematosus (SLE) is a severe autoimmune disease with an incidence of 0. 1% in the general population and mainly affects young
-
Nat Med: A new breakthrough in CAR-T cell therapy: Successfully treating multiple patients
Time of Update: 2022-10-02
In the latest paper, the research team reported that five other patients with refractory systemic lupus erythematosus improved after treatment with CAR-T cells, with no recurrence at up to 17 months of follow-up and no drug remission.
-
Long-established brands reshape brand value in multiple dimensions
Time of Update: 2022-09-30
Whether it is the launch of new lemonade in Arctic Ocean or the two-pot head chocolate hazelnut stuffed mooncake brought by Centennial Yili, they are constantly creating new experiences for products, redefining long-established brands in consumer perception, thereby strengthening users' good feelings about the brand.
-
The "gut" is a long way to go, step by step | A classic case of mCRC treated with multiple lines of treatment, OS has exceeded 39 months
Time of Update: 2022-09-07
*For medical professional reading reference onlyStandardized diagnosis and treatment and whole-process management of advanced colorectal cancer bring survival and "excellent" to patientsUp to now, col
-
A 23-year-old girl drank Coke as water and was found to have multiple acute diseases. What
Time of Update: 2022-09-06
Recently, in Zhengzhou, Henan, a 23-year-old girl suffered from diabetic ketoacidosis due to long-term drinking of Coke, and was accompanied by various diseases such as sepsis and acute kidney injury, which was life-threatening .
-
Neurology: Long-term efficacy of ponimod in the treatment of relapsing-remitting multiple sclerosis
Time of Update: 2022-09-06
0000000000200606 A recent study published in the journal Neurology assessed the dose-response relationship and wavelet of 10, 20, and 40 mg of ponimod using a combined data analysis of the Phase 2 core and extension studies in patients with relapsing multiple sclerosis (RRMS).
-
PSA deep and rapid decline, OS for a long time "K" period, advanced prostate cancer with multiple
Time of Update: 2022-06-05
During the patient's treatment, the symptoms related to bone metastases and primary lesions were significantly improved, highlighting the excellent efficacy and safety of ADT + apalutamide combination therapy .
-
New study finds a long-neglected key factor in triggering multiple types of cancer
Time of Update: 2022-05-02
▲ The presence of clustered mutations on several representative driver genes is associated with changes in patient survival (Image source: Reference [1])The researchers also identified multiple factors that contribute to such aggregated somatic mutations, such as polybasic substitutions mostly produced by smoking or ultraviolet radiation .
-
J Clin Oncol: Long-term efficacy of B-cell maturation antigen and CD19 chimeric antigen receptor T-cell combination therapy in multiple myeloma
Time of Update: 2022-04-24
Combination of anti-B-cell maturation antigen and anti-CD19 chimeric antigen receptor T cells induces durable remission in patients with refractory or relapsed multiple myeloma, with a median progression-free survival of 18.